Back to compounds

COMPOUND PROFILE / SMALL MOLECULES

AZD5004 / ECC5004.

Research draft

AZD5004, previously ECC5004 and also called elecoglipron, is an oral small-molecule GLP-1 receptor agonist.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

AZD5004, previously ECC5004 and also called elecoglipron, is an oral small-molecule GLP-1 receptor agonist.

CLASSIFICATIONSmall molecules
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It activates GLP-1 receptors without being a peptide.

Human research

First-in-human research and the randomised VISTA trial provide clinical development evidence.

Preclinical & other research

Receptor experiments and nonclinical studies characterised target activity.

Safety & unknowns

Gastrointestinal effects and longer-term safety need formulation-specific evaluation.

Regulatory status

Investigational candidate; do not transfer another GLP-1 product's authorisation.

Reported use & evidence

Research profile draft

The supplied AZD5004 / ECC5004 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds